Table 15.
Five-Year Total, Annual Average Totala, and Average Annual Age-Adjusted Incidence Ratesb with 95% Confidence Intervals for Children and Adolescents (Ages 0-19 Years) by Histopathology and Sex, CBTRUS Statistical Report: US Cancer Statistics – NPCR and SEER, 2015-2019
| Histopathology | Total | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | |
| Diffuse Astrocytic and Oligodendroglial Tumors | 2,102 | 420 | 0.51 (0.49-0.54) | 1,153 | 231 | 0.55 (0.52-0.58) | 949 | 190 | 0.47 (0.44-0.51) |
| Diffuse astrocytoma | 878 | 176 | 0.21 (0.20-0.23) | 475 | 95 | 0.23 (0.21-0.25) | 403 | 81 | 0.20 (0.18-0.22) |
| Anaplastic astrocytoma | 332 | 66 | 0.08 (0.07-0.09) | 188 | 38 | 0.09 (0.08-0.10) | 144 | 29 | 0.07 (0.06-0.08) |
| Glioblastoma | 695 | 139 | 0.17 (0.16-0.18) | 389 | 78 | 0.19 (0.17-0.21) | 306 | 61 | 0.15 (0.14-0.17) |
| Oligodendroglioma | 145 | 29 | 0.04 (0.03-0.04) | 71 | 14 | 0.03 (0.03-0.04) | 74 | 15 | 0.04 (0.03-0.05) |
| Anaplastic oligodendroglioma | 16 | 3 | 0.00 (0.00-0.01) | -- | -- | -- | -- | -- | -- |
| Oligoastrocytic tumors | 36 | 7 | 0.01 (0.01-0.01) | -- | -- | -- | -- | -- | -- |
| Other Astrocytic Tumors | 4,382 | 876 | 1.08 (1.04-1.11) | 2,308 | 462 | 1.11 (1.06-1.15) | 2,074 | 415 | 1.04 (1.00-1.09) |
| Pilocytic astrocytoma | 3,885 | 777 | 0.95 (0.92-0.98) | 2,033 | 407 | 0.98 (0.93-1.02) | 1,852 | 370 | 0.93 (0.89-0.97) |
| Unique astrocytoma variants | 497 | 99 | 0.12 (0.11-0.13) | 275 | 55 | 0.13 (0.12-0.15) | 222 | 44 | 0.11 (0.10-0.13) |
| Malignant | 230 | 46 | 0.06 (0.05-0.06) | 114 | 23 | 0.05 (0.05-0.07) | 116 | 23 | 0.06 (0.05-0.07) |
| Non-Malignant | 267 | 53 | 0.07 (0.06-0.07) | 161 | 32 | 0.08 (0.07-0.09) | 106 | 21 | 0.05 (0.04-0.06) |
| Ependymal Tumors | 1,185 | 237 | 0.29 (0.27-0.31) | 683 | 137 | 0.33 (0.30-0.35) | 502 | 100 | 0.25 (0.23-0.27) |
| Malignant | 966 | 193 | 0.24 (0.22-0.25) | 548 | 110 | 0.26 (0.24-0.29) | 418 | 84 | 0.21 (0.19-0.23) |
| Non-Malignant | 219 | 44 | 0.05 (0.05-0.06) | 135 | 27 | 0.06 (0.05-0.08) | 84 | 17 | 0.04 (0.03-0.05) |
| Other Gliomas | 3,188 | 638 | 0.78 (0.76-0.81) | 1,577 | 315 | 0.76 (0.72-0.80) | 1,611 | 322 | 0.81 (0.77-0.85) |
| Glioma malignant, NOS | 3,160 | 632 | 0.78 (0.75-0.80) | -- | -- | -- | -- | -- | -- |
| Other neuroepithelial tumors | 28 | 6 | 0.01 (0.00-0.01) | -- | -- | -- | -- | -- | -- |
| Neuronal and Mixed Neuronal-Glial Tumors | 2,090 | 418 | 0.51 (0.49-0.53) | 1,187 | 237 | 0.57 (0.54-0.60) | 903 | 181 | 0.45 (0.42-0.48) |
| Malignant | 120 | 24 | 0.03 (0.02-0.04) | 60 | 12 | 0.03 (0.02-0.04) | 60 | 12 | 0.03 (0.02-0.04) |
| Non-Malignant | 1,970 | 394 | 0.48 (0.46-0.50) | 1,127 | 225 | 0.54 (0.51-0.57) | 843 | 169 | 0.42 (0.39-0.45) |
| Choroid Plexus Tumors | 407 | 81 | 0.10 (0.09-0.11) | 235 | 47 | 0.11 (0.10-0.13) | 172 | 34 | 0.09 (0.07-0.10) |
| Malignant | 98 | 20 | 0.02 (0.02-0.03) | 63 | 13 | 0.03 (0.02-0.04) | 35 | 7 | 0.02 (0.01-0.02) |
| Non-Malignant | 309 | 62 | 0.08 (0.07-0.08) | 172 | 34 | 0.08 (0.07-0.10) | 137 | 27 | 0.07 (0.06-0.08) |
| Tumors of the Pineal Region | 215 | 43 | 0.05 (0.05-0.06) | 100 | 20 | 0.05 (0.04-0.06) | 115 | 23 | 0.06 (0.05-0.07) |
| Malignant | 179 | 36 | 0.04 (0.04-0.05) | -- | -- | -- | -- | -- | -- |
| Non-Malignant | 36 | 7 | 0.01 (0.01-0.01) | -- | -- | -- | -- | -- | -- |
| Embryonal Tumors | 2,338 | 468 | 0.58 (0.55-0.60) | 1,406 | 281 | 0.68 (0.64-0.71) | 932 | 186 | 0.47 (0.44-0.50) |
| Medulloblastoma | 1,626 | 325 | 0.40 (0.38-0.42) | 1,047 | 209 | 0.50 (0.47-0.54) | 579 | 116 | 0.29 (0.27-0.32) |
| Atypical teratoid/rhabdoid tumor | 372 | 74 | 0.09 (0.08-0.10) | 191 | 38 | 0.09 (0.08-0.11) | 181 | 36 | 0.09 (0.08-0.11) |
| All other embryonal | 340 | 68 | 0.08 (0.07-0.09) | 168 | 34 | 0.08 (0.07-0.09) | 172 | 34 | 0.09 (0.07-0.10) |
| Tumors of Cranial and Spinal Nerves | 1,173 | 235 | 0.29 (0.27-0.30) | 622 | 124 | 0.30 (0.27-0.32) | 551 | 110 | 0.27 (0.25-0.30) |
| Nerve sheath tumors | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other tumors of cranial and spinal nerves | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Tumors of Meninges | 1,252 | 250 | 0.30 (0.29-0.32) | 610 | 122 | 0.29 (0.27-0.31) | 642 | 128 | 0.32 (0.30-0.35) |
| Meningiomas | 671 | 134 | 0.16 (0.15-0.18) | 313 | 63 | 0.15 (0.13-0.17) | 358 | 72 | 0.18 (0.16-0.20) |
| Malignant | 21 | 4 | 0.01 (0.00-0.01) | -- | -- | -- | -- | -- | -- |
| Non-Malignant | 650 | 130 | 0.16 (0.15-0.17) | -- | -- | -- | -- | -- | -- |
| Mesenchymal tumors | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Primary melanocytic lesions | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Lymphomas and Hematopoietic Neoplasms | 133 | 27 | 0.03 (0.03-0.04) | 75 | 15 | 0.04 (0.03-0.04) | 58 | 12 | 0.03 (0.02-0.04) |
| Lymphoma | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other hematopoietic neoplasms | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Germ Cell Tumors | 863 | 173 | 0.21 (0.20-0.23) | 595 | 119 | 0.28 (0.26-0.31) | 268 | 54 | 0.13 (0.12-0.15) |
| Malignant | 770 | 154 | 0.19 (0.18-0.20) | 536 | 107 | 0.26 (0.23-0.28) | 234 | 47 | 0.12 (0.10-0.13) |
| Non-Malignant | 93 | 19 | 0.02 (0.02-0.03) | 59 | 12 | 0.03 (0.02-0.04) | 34 | 7 | 0.02 (0.01-0.02) |
| Tumors of Sellar Region | 4,530 | 906 | 1.10 (1.07-1.13) | 1,406 | 281 | 0.67 (0.64-0.71) | 3,124 | 625 | 1.55 (1.49-1.60) |
| Tumors of the pituitary | 3,723 | 745 | 0.90 (0.87-0.93) | 954 | 191 | 0.45 (0.43-0.48) | 2,769 | 554 | 1.37 (1.32-1.42) |
| Craniopharyngioma | 807 | 161 | 0.20 (0.18-0.21) | 452 | 90 | 0.22 (0.20-0.24) | 355 | 71 | 0.18 (0.16-0.20) |
| Unclassified Tumors | 1,481 | 296 | 0.36 (0.34-0.38) | 779 | 156 | 0.37 (0.35-0.40) | 702 | 140 | 0.35 (0.33-0.38) |
| Hemangioma | 486 | 97 | 0.12 (0.11-0.13) | 260 | 52 | 0.12 (0.11-0.14) | 226 | 45 | 0.11 (0.10-0.13) |
| Neoplasm, unspecified | 811 | 162 | 0.20 (0.19-0.21) | 422 | 84 | 0.20 (0.18-0.22) | 389 | 78 | 0.19 (0.18-0.21) |
| Malignant | 213 | 43 | 0.05 (0.05-0.06) | 114 | 23 | 0.05 (0.05-0.07) | 99 | 20 | 0.05 (0.04-0.06) |
| Non-Malignant | 598 | 120 | 0.15 (0.13-0.16) | 308 | 62 | 0.15 (0.13-0.17) | 290 | 58 | 0.14 (0.13-0.16) |
| All other | 184 | 37 | 0.05 (0.04-0.05) | 97 | 19 | 0.05 (0.04-0.06) | 87 | 17 | 0.04 (0.03-0.05) |
| Malignant | 40 | 8 | 0.01 (0.01-0.01) | 19 | 4 | 0.01 (0.01-0.01) | 21 | 4 | 0.01 (0.01-0.02) |
| Non-Malignant | 144 | 29 | 0.04 (0.03-0.04) | 78 | 16 | 0.04 (0.03-0.05) | 66 | 13 | 0.03 (0.03-0.04) |
| TOTAL c | 25,339 | 5,068 | 6.20 (6.12-6.27) | 12,736 | 2,547 | 6.10 (6.00-6.21) | 12,603 | 2,521 | 6.29 (6.18-6.40) |
| Malignant | 14,385 | 2,877 | 3.53 (3.47-3.59) | 7,854 | 1,571 | 3.77 (3.69-3.85) | 6,531 | 1,306 | 3.28 (3.20-3.36) |
| Non-Malignant | 10,954 | 2,191 | 2.67 (2.62-2.72) | 4,882 | 976 | 2.33 (2.27-2.40) | 6,072 | 1,214 | 3.02 (2.94-3.09) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histopathologies not presented in this table.
-- Counts and rates are not presented when fewer than 16 cases were reported for the specific category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; CI, confidence interval; NOS, not otherwise specified.